This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Craig-Hallum Reaffirms Their Buy Rating on Actuate Therapeutics, Inc. (ACTU)
Craig-Hallum analyst Albert Lowe maintained a Buy rating on Actuate Therapeutics, Inc. today and set a price target of $25.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Lowe covers the Healthcare sector, focusing on stocks such as Rezolute, Atossa Therapeutics, and Eledon Pharmaceuticals. According to TipRanks, Lowe has an average return of 25.8% and a 56.92% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Actuate Therapeutics, Inc. with a $21.67 average price target.
Based on Actuate Therapeutics, Inc.’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $5.41 million. In comparison, last year the company had a GAAP net loss of $5.97 million
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
